Merck & Co., Inc. Proceeds from Issuance of Debt
Merck & Co., Inc. (MRK) reported Proceeds from Issuance of Debt of $5.96 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2026-08-07
- Merck & Co., Inc. proceeds from issuance of debt for the quarter ending 2025-12-31 was $7.92B.
- Merck & Co., Inc. proceeds from issuance of debt for the quarter ending 2025-09-30 was $5.96B.
- Merck & Co., Inc. proceeds from issuance of debt for the quarter ending 2024-12-31 was $0.00.
- Merck & Co., Inc. proceeds from issuance of debt for the quarter ending 2024-09-30 was -$1.00M.
- Merck & Co., Inc. proceeds from issuance of debt for fiscal 2025 was $13.88B, a 285.66% increase from fiscal 2024.
- Merck & Co., Inc. proceeds from issuance of debt for fiscal 2024 was $3.60B, a 39.40% decline from fiscal 2023.
- Merck & Co., Inc. proceeds from issuance of debt for fiscal 2023 was $5.94B.
- Merck & Co., Inc. proceeds from issuance of debt for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Debt 1 month | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.96B 10-Q · filed 2026-08-07 | ||||
| 2025-12-31 | $7.92B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $13.88B derived: sum of 2 quarters · filed 2026-02-24 | $13.88B 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $5.96B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.96B 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-07 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$1.00M derived: sum of 2 quarters · filed 2026-02-24 | $3.60B 10-K · filed 2026-02-24 | ||
| 2024-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.60B 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $3.60B 10-Q · filed 2025-08-05 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$7.00M derived: sum of 2 quarters · filed 2026-02-24 | $5.94B 10-K · filed 2026-02-24 | ||
| 2023-09-30 | -$7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $5.94B 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $5.95B 10-Q · filed 2024-08-05 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 | ||||
| 2014-10-31 | $3.10B 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |